Primary Central Nervous System Diffuse Large B Cell Lymphoma (PCNS-DLBCL)
Study summary
PCNS-DLBCL is a rare extranodal non-Hodgkin lymphoma that primarily affects the brain, spine, or vitreoretinal space. The prognosis for PCNS-DLBCL is significantly worse than that for its systemic counterpart.
Understanding how and where this tumor initiates, and how it survives or depends on the microenvironment of the CNS is key to understanding the underlying biology and identifying reliable biomarkers for selecting personalized therapy or for biologically directed therapy that could improve the cure rate of CNS lymphomas.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
1. Be an adult immunocompetent patient who received a PCNS-DLBCL diagnosis according to the WHO-HAEM5 criteria between 2018 and 2024.
2. Availability of formalin-fixed paraffin-embedded (FFPE) diagnostic tumor material.
3. Availability of the baseline and follow-up annotations
Exclusion Criteria:
1. Established immunodeficiency conditions.
2. Secondary CNS localizations of DLBCL
3. Transformed DLBCL
Primary outcome measure(s)
Prevalence of non-GC phenotype — 12 months: from the end of samples collection to the end of study analysis
Prevalence of mutations, copy number abnormalities, and structural variants — 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by genetic lesions — 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by gene expression signatures — 12 months: from the end of samples collection to the end of study analysis
Prevalence of PCNS-DLBCL molecular subtypes defined by genetic methylation profile — 12 months: from the end of samples collection to the end of study analysis
Trial sites (2)
Facility
City
Region
Status
Fondazione IRCCS Policlinico San Matteo Pavia
Pavia
Italy
Oncology Institute of Southern Switzerland and Institute of Oncology Research
Bellinzona
Switzerland
More International Extranodal Lymphoma Study Group (IELSG) trials in Switzerland
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
